Merck sponsored studies that showed Vioxx doubled the risk of heart attacks, strokes, and blood clots but omitted three heart attacks from their published study in the New England Journal. A person in charge of the drug's safety modelboard was given a contract to consult for Merck after they decided to stop counting cardiovascular events a month before the trial ended.